Cargando…
Searching for treatments for non-G12C-KRAS mutant cancers
KRAS mutations drive a wide variety of cancers. Drugs targeting the protein product of KRAS(G12C) mutations are currently being evaluated show preliminary efficacy in clinical trials. A clinical trial of VS-6766, a dual RAF–MEK inhibitor, has reported early single agent activity in non-G12C mutated...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8405631/ https://www.ncbi.nlm.nih.gov/pubmed/33859342 http://dx.doi.org/10.1038/s41416-021-01357-2 |